Sutro Biopharma, Inc. (STRO)

Market Cap	88.58M
Revenue (ttm)	62.04M
Net Income (ttm)	-227.46M
Shares Out	84.36M
EPS (ttm)	-2.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,932,634
Open	0.856
Previous Close	0.875
Day's Range	0.832 - 1.080
52-Week Range	0.520 - 5.170
Beta	1.70
Analysts	Hold
Price Target	6.14 (+484.76%)
Earnings Date	May 12, 2025

About STRO

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in P...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 27, 2018
• Employees: 310
• Stock Exchange: NASDAQ
• Ticker Symbol: STRO
• Website: https://www.sutrobio.com

Financial Performance

In 2024, Sutro Biopharma's revenue was $62.04 million, a decrease of -59.64% compared to the previous year's $153.73 million. Losses were -$227.46 million, 113.0% more than in 2023.

Analyst Forecast

According to 8 analysts, the average rating for STRO stock is "Hold." The 12-month stock price forecast is $6.14, which is an increase of 484.76% from the latest price.

Price Target

$6.14

(484.76% upside)

Analyst Consensus: Hold